Follicular Lymphoma | Tumor

Is It a Symptom of Cancer, Injury, Aging, Something Else… Or Nothing?

January 17th 2024, 6:00pm

Article

Whenever I experience a new ache or patch of itchy skin, I immediately think it's a health issue — or a recurrence.

Kymriah Elicits Long-Lasting Responses in R/R Follicular Lymphoma

December 11th 2023, 11:00pm

Article

Researchers reported long-lasting responses and no new safety concerns in patients with relapsed/refractory follicular lymphoma during the 2023 ASH Annual Meeting and Exposition.

Unhelpful Advice I Received During Cancer

November 20th 2023, 11:00pm

Article

Please don’t tell me I have the “good” kind of cancer or comment on how much weight I’ve lost.

Odronextamab Gets Priority Review for Relapsed, Refractory Follicular Lymphoma, DLBCL

October 15th 2023, 7:00pm

Article

The Food and Drug Administration will speed up the review of odronextamab for patients with relasped or refractory follicular lymphoma or diffuse large B-cell lymphoma.

Access to Therapies Through Clinical Trials ‘a Blessing’ for Lymphoma, Other Cancers

April 18th 2023, 7:00pm

Article

One patient was able to access a therapy for follicular lymphoma before it was approved by the FDA, which allowed him to help future patients through his experience.

FDA Approves Lunsumio to Treat Relapsed/Refractory Follicular Lymphoma

December 23rd 2022, 2:01pm

Article

Patients with relapsed/refractory follicular lymphoma — a group that traditionally has limited treatment options — now have a new bispecific antibody available.

Revlimid-Rituxan Combo May Offer Alternative to Chemotherapy for Lymphoma Subtype

August 22nd 2022, 1:09pm

Article

The combination treatment demonstrated survival and safety results similar to those of chemotherapy for patients with advanced, untreated follicular lymphoma.

FDA’s Approval of Breyanzi Gives Some Patients With Lymphoma a ‘Life-Saving Therapy', Says Expert

July 8th 2022, 7:00pm

Article

The FDA approval of Breyanzi, a novel CAR-T cell therapy, provides many patients with lymphoma a new treatment option that can be used earlier in the course of their disease, according to an expert.

FDA Grants Lunsumio Priority Review for Relapsed/Refractory Follicular Lymphoma

July 7th 2022, 3:00pm

Article

The priority review comes following positive clinical trial results, which may lead to a shift in the treatment paradigm for follicular lymphoma, according to an expert.

FDA Approves Kymriah for Relapsed/Refractory Follicular Lymphoma

May 31st 2022, 1:59pm

Article

Kymriah, a CAR-T cell therapy, was approved by the Food and Drug Administration for the treatment of patients with pretreated, relapsed/refractory follicular lymphoma.